PRESS RELEASE Paris

Sanofi delivers Business EPS(1) growth of 10.3% at CER in Q3 2014

Solid sales and business EPS(1) growth at CER in the third quarter

Group sales(2) up 5.1% to 8,781 million

Growth platforms(3) increased 10.0% to 6,862 million, representing 78.1% of total sales

Business net income(1) grew 9.4% at CER to 1,935 million (+7.8% on a reported basis)

Business EPS(1) increased 10.3% at CER to 1.47

Steady sales increase in growth platforms

Diabetes grew 8.3% to 1,799 million despite increased price competition in the U.S.

Vaccines sales grew 11.2% driven by strong performance of flu vaccine and progressive supply recovery

Genzyme continued to deliver with sales growth of 24.6%

Animal Health grew 12.7% due to strong sales in the U.S. market

Significant advances in bringing new medicines to market

Cerdelga , the only oral therapy for adult Gaucher disease type 1 patients, approved in the U.S.

Detailed results from four pivotal Phase III alirocumab trials presented at the ESC congress

Final landmark Phase III efficacy study in Latin America for Dengue vaccine successfully completed

Dupilumab, an investigational therapy for moderate-to-severe atopic dermatitis, entered Phase III

Investigational rotavirus vaccine for Emerging Markets entered Phase III

Global licensing agreement announced for Afrezza , a new rapid-acting inhaled insulin

Financial guidance for 2014 confirmed

2014 business EPS(1) is expected to be between 6% to 8% higher than 2013 at CER, barring major unforeseen adverse events

Sanofi Chief Executive Officer, Christopher A. Viehbacher commented:

We are pleased with our performance in the third quarter. We achieved solid Business EPS growth driven by continued strong contribution from our growth platforms, allowing us to confirm 2014 outlook. Growth platforms reached over 78% of sales and grew 10%. We have recently seen a more challenging U.S. diabetes price environment which will impact our diabetes sales throughout 2015, while growth platforms globally are expected to continue to show solid growth. At the same time, our pipeline delivered strong results, with the release of exciting Phase III data for alirocumab and our Dengue vaccine, the entry of dupilumab in Phase III as well as the FDA approval of Cerdelga and the licensing of Afrezza .

(1) See Appendix 8 for definitions of financial indicators; (2) Growth in net sales is expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 8 for a definition); (3) See page 2

Investor Relations: (+) 33 1 53 77 45 45 - E-mail: IR@sanofi.com - Media Relations: (+) 33 1 53 77 46 46 - E-mail: MR@sanofi.com

Web site: www.sanofi.com Mobile app : SANOFI IR available on the App Store and Google Play

2014 third-quarter and 9-month figures

In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income(1) is a non-GAAP financial measure. The consolidated income statement for 9M 2014 is provided in Appendix 4 and a reconciliation of business net income to consolidated net income in Appendix 3. Consolidated net income for 9M 2014 was 3,051 million compared to 2,656 million for 9M 2013. Consolidated EPS for 9M 2014 was 2.32 versus 2.01 for 9M 2013. Consolidated EPS for Q3 2014 was 0.91 versus 0.92 for Q3 2013.

2014 third-quarter and 9-month sales

Unless otherwise indicated, all sales growth figures in this press release are stated at constant exchange rates(1).

In the third quarter of 2014, Sanofi generated sales of 8,781 million, an increase of 4.1% on a reported basis. Exchange rate movements had a negative effect of 1.0 percentage point primarily reflecting the strength of the euro versus other currencies, in particular the Argentine Peso, Japanese Yen and Russian Ruble.

Year-to-date sales increased 0.8% to 24,698 million on a reported basis. Exchange rate movements had an unfavorable effect of 4.2 percentage points.

In the third quarter, sales of the Group s growth platforms increased 10.0% to 6,862 million, driven by the performance of Genzyme (up 24.6%), Vaccines (up 11.2%), Animal Health (up 12.7%) and Other Innovative Products (up 18.0%). The Group s growth platforms accounted for 78.1% of total consolidated sales in the third quarter, up from 74.7% in the third quarter of 2013. Year-to-date sales of growth platforms reached 18,801 million, an increase of 10.8%, and accounted for 76.1% of total consolidated sales compared with 72.5% in the first nine month of 2013.

(a) Includes product launches since 2009 which do not belong to the other Growth Platforms listed above: Multaq , Jevtana , Zaltrap , Auvi-Q and Mozobil .

(b) World excluding the U.S. and Canada, Western Europe, Japan, Australia and New Zealand.

(c) Excluding generics in Brazil, sales in Emerging Markets grew 6.1% in 9M 2014.

(1) See Appendix 8 for definitions of financial indicators.

Third-quarter sales for the Pharmaceuticals business grew 3.4% to 6,815 million, driven by Emerging Markets. Year-to-date sales for Pharmaceuticals increased 5.1% to 20,332 million.

Third-quarter sales of the Diabetes division reached 1,799 million, an increase of 8.3%. Year-to-date sales of the Diabetes division increased 12.5% to 5,249 million. Lantus sales increased 8.1% to 1,567 million in the third quarter. In the U.S., third-quarter sales of Lantus reached 1,042 million, an increase of 5.8%, reflecting increasing competitive pressure at the payor level. Lantus SoloSTAR represented 62.2% of total Lantus sales, versus 57.4% for the same period in 2013. In Emerging Markets, Lantus sales grew 19.7% to 232 million in the third quarter, reflecting good performance in China, Turkey, Middle East, Mexico and Africa. In Western Europe, sales of Lantus recorded a strong performance with sales up 9.5% to 222 million driven by Germany, France and Italy. Year-to-date sales of Lantus reached 4,572 million, up 12.5%.

Sanofi has recently concluded payor negotiations in the U.S. and has secured favorable formulary positions for Lantus with key payors. The level of rebates required to maintain these positions has increased significantly due to aggressive discounting by competitors. The rebates will not change the Group s Business EPS guidance for 2014. The increased rebates in the U.S. and the impact of the Affordable Care Act will continue in 2015. Sanofi expects to mitigate this impact on the Diabetes division in 2015 through the launches of Toujeo and Afrezza as well as continued strong growth in Emerging Markets. Therefore, global sales of the Diabetes division are expected to be broadly stable in 2015.

Third-quarter sales of Amaryl were 87 million, down 2.2%. In Emerging Markets, Amaryl sales increased 6.2% to 68 million. Year-to-date sales of Amaryl were 269 million (up 0.7%).

Apidra sales increased 21.9% to 88 million. The product recorded strong growth in all territories. In the U.S., sales were up 20.7% to 35 million. In Emerging Markets, sales were up 25.0% to 19 million and in Western Europe, sales grew 19.0% to 26 million. Year-to-date sales of Apidra grew 20.3% to 240 million.

Third-quarter and year-to-date sales of Lyxumia were 8 million and 19 million, respectively.

In August, Sanofi and MannKind entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza , a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015. Under the collaboration and license agreement, Sanofi will be responsible for global commercial, regulatory and development activities.

Sales of Consumer Healthcare products (CHC) were 819 million in the third quarter, an increase of 12.9%. Several products (amounting to 64 million in sales) previously recorded in prescription pharmaceuticals in the third quarter of 2013 were transferred to Consumer Healthcare products. Excluding this category change, sales of CHC grew 4.0% driven by the success of the Nasacort Rx-to-OTC switch in the U.S. and good performance in Emerging Markets (+7.8%). Sales of Nasacort Allergy 24HR nasal spray, which has been available over-the-counter (OTC) in the U.S. since February, were 18 million in the third quarter in the U.S.

Year-to-date sales of CHC were 2,520 million, an increase of 17.3%. Excluding the category change mentioned above ( 205 million in the first nine month of 2013), CHC sales grew 7.6%.

Sales of Genzyme increased 24.6% to 649 million in the third quarter driven by the growth of Aubagio and Fabrazyme . Sales grew 28.2% to 259 million in the U.S., 25.0% to 207 million in Western Europe and 19.8% to 124 million in Emerging Markets. Year-to-date sales of Genzyme reached 1,858 million, an increase of 25.1%.

Third quarter-sales of Cerezyme grew 9.1% to 175 million, reflecting double digit-growth in Western Europe (up 15.4% to 60 million). Sales of Cerezyme grew 7.0% to 56 million and 4.3% to 48 million in Emerging Markets and the U.S., respectively. Year-to-date sales of Cerezyme grew 8.3% to 518 million. In August, the FDA approved Cerdelga , the only first-line oral therapy for Gaucher disease type 1 patients (GD1). The vast majority of adult GD1 patients should be eligible for Cerdelga , which is now available in the U.S.

Fabrazyme continued its strong performance with sales of 116 million, up 21.9% in the third quarter driven by Western Europe (up 40.0% to 28 million) and Emerging Markets (up 33.3% to 15 million). In the U.S., sales of Fabrazyme reached 58 million, an increase of 14.0%. Year-to-date sales of Fabrazyme grew 26.2% to 337 million.

Third-quarter sales of Myozyme /Lumizyme increased 9.4% to 138 million, driven by Emerging Markets (up 42.1% to 25 million). In the U.S. and Western Europe, sales were 35 million (up 9.4%) and 69 million (up 1.5%), respectively. Year-to-date sales of Myozyme /Lumizyme grew 9.2% to 392 million.

Third-quarter sales of Aubagio reached 112 million versus 44 million in the third quarter of 2013. In the U.S., sales of Aubagio were 87 million versus 44 million in the third quarter of 2013. In Western Europe, where the launch of the product started in the fourth quarter of 2013, sales reached 18 million in the third quarter. The product is mainly commercially available in the U.S., Germany, Switzerland, Nordic countries, Canada, Argentina and Australia. Year-to-date sales of Aubagio totaled 287 million, up 205.2%.

In October, the Food and Drug Administration (FDA) approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of Aubagio in the product s U.S. label. Aubagio is the only oral treatment to significantly slow progression of disability in two Phase III studies of patients with relapsing multiple sclerosis (TEMSO and TOWER), and to have positive data on early multiple sclerosis in its label.

Third quarter and year-to-date sales of Lemtrada were 7 million and 18 million, respectively. In May, the U.S. Food and Drug Administration (FDA) accepted for review the resubmission of the supplemental Biologics License Application (sBLA) seeking approval of Lemtrada for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA.

Other Innovative Products(4)

Other Innovative Products increased 18.0% to 227 million in the third quarter and 17.9% to 606 million in the first nine months.

Sales of Multaq were 76 million, up 13.4% in the third quarter. Year-to-date sales of the product increased 11.1% to 215 million.

Third-quarter sales of Jevtana increased 15.3% to 67 million driven by launches in Western Europe and Emerging Markets. Year-to-date sales of Jevtana grew 23.6% to 199 million.

Third-quarter sales of Auvi-Q were 37 million (up 26.7%). Year-to-date sales of the product were 63 million (up 32.7%).

In the third quarter, sales of Zaltrap reached 18 million, an increase of 30.8% driven by recent launches in Western Europe which offset lower sales in the U.S. Year-to-date sales of the product were 49 million (up 28.9%).

Other Pharmaceutical Products

(4) Includes new product launches which do not belong to the other Growth Platforms

Sales of Plavix grew 9.0% to 450 million in the third quarter, driven by strong performance in Emerging Markets (up 21.3% to 203 million) and Japan (up 8.7% to 190 million). The performance of the product in Emerging Markets was driven by China where sales grew 47.1% to 125 million. Year-to-date sales of Plavix increased 5.8% to 1,362 million.

Third-quarter sales of Lovenox were up 7.2% to 426 million sustained by the strong performance in Emerging Markets where sales increased 16.9% to 147 million driven by China and Latin America. In Western Europe, sales of the product grew 5.8% to 221 million. Year-to-date sales of Lovenox totaled 1,263 million, an increase of 2.9%.

Aprovel /Avapro generated sales of 178 million in the third quarter, down 14.8%, reflecting generic competition in Western Europe where sales decreased 47.4% to 41 million. In Emerging Markets, sales of Aprovel /Avapro increased 9.3% to 105 million driven by China. Year-to-date sales of Aprovel /Avapro were 550 million, down 17.9%.

Third-quarter sales of Renvela /Renagel were 162 million in the third quarter, down 13.4%. In the U.S., sales of the product decreased 22.0% to 103 million reflecting the impact of the agreement with Impax which was granted a license to sell a limited allotment of bottles of an authorized generic version of Renvela tablets in the U.S. starting from April 2014. The specific allotment corresponds to up to 10% of the total 2013 sevelamer sales in the U.S. In Emerging Markets, sales of Renvela /Renagel increased 22.2% to 22 million. In Western Europe sales were stable at 32 million. Year-to-date sales of Renvela /Renagel were 471 million, a decrease of 9.0%.

In the third quarter, sales of Allegra as a prescription drug were 32 million, down 52.1% (excluding the change of category, sales decreased 19.0%) and sales of the Ambien family of products were 78 million, down 16.0%, reflecting generic competition in Japan for both products. Year-to-date sales of Allegra and the Ambien family of products were 151 million and 229 million, respectively.

Third-quarter and year-to-date sales of Taxotere decreased 28.6% ( 59 million) and 31.7% ( 195 million), respectively, mainly due to generic erosion. Third-quarter and year-to-date sales of Eloxatin decreased 12.0% ( 43 million) and 14.2% ( 136 million), respectively.

Third-quarter sales of Generics increased 8.3% to 451 million reflecting the recovery in Brazil where sales were 76 million. Third-quarter sales of Generics decreased 3.9% in Western Europe (to 125 million) and 24.3% in the U.S. (to 28 million). In Emerging Markets, sales of Generics grew 19.8% to 287 million driven by the recovery in Brazil. Year-to-date sales of Generics increased 23.2% to 1,338 million.

Third-quarter consolidated sales of Sanofi Pasteur increased 11.2% to 1,451 million driven by strong performance of influenza vaccines in the U.S. and in Emerging Markets as well as continued gradual recovery of Pentacel and Adacel in the U.S. Year-to-date consolidated sales of Sanofi Pasteur increased 4.1% to 2,797 million.

Third-quarter sales of Influenza vaccines grew 15.0% to 650 million due to strong influenza vaccines sales in the U.S. and in Emerging Markets. In the U.S., Sanofi Pasteur s strategy to offer differentiating vaccines leads to a strong uptake of Fluzone High-Dose for elderly people and Fluzone Quadrivalent vaccine, a four-strain influenza vaccine. Year-to-date sales of influenza vaccines increased 16.0% to 844 million.

Sales of Polio/Pertussis/Hib vaccines increased 7.4% to 259 million in the third quarter. In the U.S., Polio/Pertussis/Hib vaccines sales were 97 million, an increase of 94.0% sustained by the continued gradual recovery of Pentacel . In Emerging Markets sales of Polio/Pertussis/Hib vaccines decreased 20.6% to 120 million reflecting lower sales of Pentaxim and Polio vaccines in Asia. Year-to-date sales of Polio/Pertussis/Hib vaccines were 754 million, down 2.4%.

Third-quarter sales of Menactra were 174 million, down 10.3%. In the U.S., lower sales of Menactra reflected phasing of public orders while strong market share was maintained. Year-to-date sales of Menactra were 327 million down 6.9%.

Sales of Travel and Other Endemic vaccines were down 3.0% to 99 million and up 5.9% to 277 million in the third quarter and the first nine months of 2014, respectively.

Third-quarter sales of Adult Booster vaccines increased 54.8% to 131 million, reflecting supply improvement and positive phasing of Adacel sales. Year-to-date sales of Adult booster vaccines were 295 million, an increase of 3.1%.

Sanofi Pasteur MSD (not consolidated), the joint venture with Merck & Co. in Europe, reported stable sales at 295 million. Increased sales of Zostavax were offset by lower sales of Gardasil . Year-to-date sales of Sanofi Pasteur MSD were 608 million, down 3.4% on a reported basis.

Third-quarter sales of Animal Health increased 12.7% to 515 million driven by the launch of NexGard and the strong performance of the production animal segment. In the U.S., Animal Health sales grew 23.2% to 220 million. Year-to-date sales of Animal Health increased 5.3% to 1,569 million.

Third-quarter sales of the Companion Animals segment increased 13.3% to 317 million, reflecting the NexGard launch as well as performance of pet vaccines and Heartgard . Merial launched, its next generation flea and tick product for dogs, NexGard , in the U.S. in the first quarter and in several European countries during the first nine months of the year. Third-quarter sales of NexGard reached 27 million of which 23 million was generated in the U.S. Sales of the Companion Animals segment increased 19.5% in the U.S. to 185 million. Year-to-date sales of the Companion Animals segment increased 5.9% to 1,006 million.

Third-quarter sales of the Production Animals segment increased 11.7% to 198 million driven by double-digit growth of products for ruminants and swine. Furthermore, favorable phasing for tenders of Veterinary Public Health products had a positive impact in the quarter. Sales of the Production Animals segment increased 4.2% to 563 million year-to-date.

Net sales by geographic region

(a) World less the U.S., Canada, Western Europe, Japan, Australia and New Zealand;

(b) France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark;

(c) Japan, Canada, Australia and New Zealand

In the third quarter, sales in Emerging Markets grew 7.6% to 2,776 million. Pharmaceuticals sales increased 9.2% driven by Diabetes (up 17.5%), Genzyme (up 19.8%), and Generics (up 19.8%). Sales in China grew 10.5% to 386 million reflecting strong performance of Pharmaceuticals (up 20.1%) partially offset by Vaccines notably due to lower sales of Pentaxim . In China, the Pharmaceuticals sales growth was driven by Plavix , Lantus and Aprovel . Sales in Eastern Europe, Russia and Turkey were up 4.8%, supported by good performance in Turkey and Hungary. Sales in Russia reached 195 million, an increase of 4.3%. In the Middle-East, sales grew 3.5% to 236 million. In Brazil, sales increased 17.5% to 318 million sustained by the performance of generics. Year-to-date sales in Emerging Markets increased 9.9% to 8,221 million. Excluding Brazil generics, sales in Emerging Markets grew 6.1%.

In the U.S., sales were up 7.2% to 3,208 million in the third quarter, due largely to strong performance of Genzyme (up 28.2%), Vaccines (up 15.8%) and Animal Health (up 23.2%). Year-to-date sales in the U.S. increased 8.0% to 8,192 million.

Western Europe returned to growth in the third-quarter with sales increasing 3.1% to 2,003 million. Strong performance of Genzyme (up 25.0%) was offset by the impact of generic competition to Aprovel . Year-to-date sales in Western Europe were stable at 5,909 million.

Third-quarter sales in Japan were 507 million, a decrease of 7.2%, reflecting the impact of generic competition to Allegra , Myslee , Amaryl and Taxotere partially offset by the performance of Plavix and Vaccines. Year-to-date sales in Japan were 1,569 million (down 7.4%).

Consult Appendix 6 for full overview of Sanofi s R&D pipeline

Regulatory updates since the publication of the second-quarter 2014 results on July 31, 2014 include the following:

In August, the U.S. Food and Drug Administration (FDA) approved Cerdelga (eliglustat) capsules, the only first-line oral therapy for certain adult Gaucher disease type 1 patients.

The sBLA for Lumizyme label expansion and 4,000L manufacturing process was also approved in August by the FDA. Lumizyme is now indicated for all patients with Pompe disease regardless of age or phenotype.

In September, the BLA for a pediatric hexavalent vaccine PR5i (DTP-Hep B-Polio-Hib) was submitted in the U.S.